drugset
drugset / Trial / NCT05347212

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

NCT05347212 ↗

Phase 2 Active not recruiting 30 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if the combination of nivolumab and relatlimab can help to control renal medullary carcinoma (RMC) that is locally advanced or metastatic (has spread).

Timeline

Start
2022-09-22
Primary completion
2027-07-16
Completion
2027-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 480 mg Intravenous
Subject Relatlimab Monoclonal antibody 480 mg Intravenous

Indications

kidney medullary carcinoma